BMS CA224-098, RELATIVITY 098 (Melanoma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if combining 2 drugs (relatlimab + nivolumab) is more effective than using nivolumab on its own to prevent a recurrence of melanoma. Currently, using nivolumab on its own is the standard treatment to prevent melanoma from coming back after it has been removed by surgery.
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with stage III or 4 melanoma
- Have had their tumor(s) completely removed
For more information about who can join this study, please contact the study team at email@example.com.
What is Involved?
If you choose to join this study, you will:
- Be randomly assigned (like a coin flip) to 1 of 2 groups
-- One group will get relatlimab + nivolumab after surgery
-- The other group will get nivolumab on its own after surgery
- Both groups will get dosed every 4 weeks by intravenous (IV) infusion for up to 1 year